Does the requirement for baseline CYP2C9 genotype testing alone deter you from prescribing deuruxolitinib over baricitinib or ritlecitinib for adult alopecia areata?
When selecting an oral JAK inhibitor for adult alopecia areata, how significantly do deuruxolitinib's twice-daily dosing and mandatory baseline CYP2C9 genotype testing lead you to favor once-daily alternatives (e.g., baricitinib, ritlecitinib)?
Join Mednetto vote and see how they answered.
This does not deter me from prescribing deuruxolitinib. I often have to get baseline labs, and patients are not necessarily ready to start a JAK inhibitor when we first discuss it, so the time it takes to get the results is not a deterrent. The only thing that would impact my decision is less famili...
Join for free or sign in to see the full answer
Deciding between the different oral JAK inhibitors is a nuanced process, but if the patient and I decide that deuruxolitinib is the best option, the baseline CYP2C9 genetic testing does not deter me (nor does it factor into the decision about whether it is the best option). I view the CYP2C9 test si...
Join for free or sign in to see the full answer
Yes, both the need for genotype testing and potential drug-drug interactions limit my use of deuruxolitinib.
Join for free or sign in to see the full answer